Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NCF1 | P14598 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | GALR2 | O43603 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8892258 | 0.79 | LMNA (0.45) | ALDH1A1HSD17B10CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3294386 | 0.79 | TSHR (0.46) | ALDH1A1RECQLHSD17B10CYP1A2CYP2C19 | |
| SCHEMBL3223803 | 0.77 | CYP1A2 (0.49) | CYP1A2CYP2C19CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3223791 | 0.77 | CYP1A2 (0.49) | CYP1A2CYP2C19CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5273500 | 0.75 | CYP1A2 (0.38) | ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL5275210 | 0.75 | KMT2A (0.40) | ALDH1A1CYP1A2CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL7695091 | 0.74 | KDM4E (0.45) | ALDH1A1RECQLHSD17B10CYP2D6LMNA | |
| SCHEMBL8791171 | 0.74 | RAB9A (0.44) | ALDH1A1RECQLCYP1A2CYP3A4LMNA | |
| SCHEMBL25821979 | 0.74 | MAPT (0.43) | ALDH1A1LMNAPOLBKMT2AMAPT | |
| SCHEMBL30945318 | 0.74 | ALDH1A1 (0.49) | ALDH1A1CYP1A2CYP2C19LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| CN-114667167-B | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2024-12-20 | — | — | CN | disclosed |
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| CN-114667167-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2022-06-24 | — | — | CN | disclosed |
| EP-4010080-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028643-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
| EP-2328891-B1 | NEW BENZOFURANS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS | ASTRAZENECA AB (SE) | 2017-04-05 | — | — | EP | disclosed |
| US-20120264943-A1 | Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits | ASTRAZENECA AB (SE) | 2012-10-18 | — | — | US | disclosed |
| US-8193363-B2 | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits | ASTRAZENECA AB (SE) | 2012-06-05 | — | — | US | disclosed |
| US-8193363-B2 | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits | ASTRAZENECA AB (SE) | 2012-06-05 | — | — | US | disclosed |
| US-8193363-B2 | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits | ASTRAZENECA AB (SE) | 2012-06-05 | — | — | US | disclosed |
| CN-102197036-A | Novel benzofurans suitable as precursors to compounds for imaging amyloid deposits | ASTRAZENECA AB | 2011-09-21 | — | — | CN | disclosed |
| WO-2010024769-A1 | NEW BENZOFURANS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | WO | disclosed |
| WO-2010024769-A1 | NEW BENZOFURANS SUITABLE AS PRECURSORS TO COMPOUNDS THAT ARE USEFUL FOR IMAGING AMYLOID DEPOSITS | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056796-A1 | Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056796-A1 | Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
| US-20100056796-A1 | Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | KCNH2 3956/4885SCN5A 2735/4885ALDH1A1 97/4885 |
| US-20100056796-A1 | Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits | APP, PSEN1, PSEN2 | KCNH2 4502/4885SCN5A 3268/4885ALDH1A1 2924/4885 |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | KCNH2 3956/4885SCN5A 2735/4885ALDH1A1 97/4885 |
| US-20120264943-A1 | Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits | APP, PSEN1, PSEN2 | KCNH2 4502/4885SCN5A 3268/4885ALDH1A1 2924/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | KCNH2 3771/4885SCN5A 3430/4885ALDH1A1 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.